It is important to allow adequate time at each dose level before concluding that appetite suppression is insufficient
Regular follow-up visits provide opportunities to reassess bone health status and adjust protective strategies as needed
#Ophthalmology #Ophthotwitter #Scicomm GLP-1 RAs and eye problems: A global study Ophthopedia Update:Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for type 2 diabetes (T2DM), obesity, and cardiovascular disease.13 Beyond these indications, they have shown promising clinical efficacy in conditions such as chronic kidney disease, metabolic dysfunctionassociated steatohepatitis, obstructive sleep apnea, and Parkinsons disease.46 With proven efficacy and increasing global use, there is a growing need to better understand the potential complications of GLP-1 RA therapy

5 days/week (~12 mg/day): ~13 vials 3/week (2 mg): ~12 vials 16 weeks: ~3 vials Insulin Syringes (U-100, 1 mL) Per injection: 1 syringe 8 weeks (5 days/week): ~40 syringes 16 weeks (5 days/week): ~80 syringes Bacteriostatic Water (10 mL bottles) Use ~3.0 mL per 50 mg vial for reconstitution
many clients lose even more